The potential of the market is enormous, due to the constant population growth and the high prevalence of certain diseases in the cardiovascular, respiratory and oncology…
In Conversation
Whether Taiwan’s biomedical industry can be robust will depend on the kinds of technologies we can build
Foreign multinationals and national champions eager to access innovation have understood what Sweden has to offer and are actively building bridges with the local ecosystem.
We are on the right track in terms of collaborating with the industry, and we even have more trials than patients!
Today, Sun Pharma is the biggest Indian company in Egypt and the only Indian manufacturer in the country
GSK has been in Egypt for almost 70 years and our footprint here is around driving access to medicine for the Egyptian population through our diversified…
Paradoxically, I believe you can find the most opportunities when the environment is complicated or difficult. This is why I decided to start a biotech company…
We need the regulations not to become an obstacle for clinical trials; Sweden views companies choosing to conduct clinical trials here as in the national interest
Our first investment was into PharmaEngine which several years later became a success story. Additionally, we invested in ten other corporations including Mycenax Biotech, Brim Biotechnology,…
Moving further towards biotechnology and oncology will be a major turning point in Sedico's history
As a researcher, your interests lie in seeking new knowledge and spreading it. However, that knowledge and related implications might not always be in line with…
Taiwan is an interesting market on its own and is a leading player in scientific capacity within the region
